Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.14
+0.27002.74%
Volume:2.31M
Turnover:23.59M
Market Cap:2.22B
PE:-7.17
High:10.55
Open:10.11
Low:10.06
Close:9.87
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.95
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.27
PE(LYR):-7.14

Loading ...

Ocular Therapeutix Grants Inducement Awards to New Hires, Including Options Priced at $8.4 Per Share

Reuters
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Tarsus Pharmaceuticals Q2 Sales Beat Estimates, Lifts 2026 Xdemvy Sales Outlook

Reuters
·
Aug 06

Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs

Reuters
·
Aug 06

RxSight Q2 Adjusted Loss Beats Estimates; Withdraws 2026 Guidance

Reuters
·
Aug 06

Sight Sciences Q2 Revenue Rises 20%, Beats Estimates

Reuters
·
Aug 06

Canada's Kits Eyecare Q2 Revenue Slightly Beats on Glasses Segment Growth

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

MT Newswires Live
·
Aug 04

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04

Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices

TIPRANKS
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04

Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Twist Bioscience (TWST)

TIPRANKS
·
Aug 04

Ocular Therapeutix Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Reuters
·
Aug 03

Design Therapeutics Q2 Net Loss Narrower than Expected

Reuters
·
Aug 03

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

Reuters
·
Aug 03

Ocular Therapeutix Q2 Product Revenue USD 13.48 Million

THOMSON REUTERS
·
Aug 03

Earnings Flash (OCUL) Ocular Therapeutix Posts Q2 Net Loss $0.35 a Share, vs. FactSet Est of $0.40 Loss

MT Newswires Live
·
Aug 03